Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- LDP Proposes Creation of a Japanese Version of FDA
April 21, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 21, 2008
- Eisai Discontinues Development of E2007 for Parkinson's Disease
April 21, 2008
- Takeda to Acquire Millennium for US$8.8 Billion
April 21, 2008
- Closure of Labs in Japan Consequence of a Natural Course of Events: Dr Kobayashi of PhRMA
April 21, 2008
- Shionogi to Have Own Marketing Forces in US
April 21, 2008
- Council Selects iPS Cells as Priority Technology
April 21, 2008
- Diovan Back to No.1 Position in February: Rep Track Survey
April 21, 2008
- JSRM Calls For Deregulations over Research Using Human ES Cells
April 21, 2008
- JHSF Proposes Support of Alliances
April 21, 2008
- JPMA Calls For Creation of Clinical Trials Centers
April 21, 2008
- Global Market for Drugs for Alzheimer's Disease to Expand to US$9.2 Bil.: Datamonitor
April 21, 2008
- R&D NEWS IN BRIEF（1）
April 21, 2008
- BUSINESS NEWS IN BRIEF
April 21, 2008
- R&D NEWS IN BRIEF（2）
April 21, 2008
- Orchid of India Announces Entry into Japanese Market
April 21, 2008
- NEW PRODUCTS
April 21, 2008
- Promotion of Use of Generics Starts on Full Scale
April 14, 2008
- Dr Karasawa Reelected JMA President
April 14, 2008
- Prof. S. Ushimaru Appointed as Successor of Prof. T. Tsuchida at Chuikyo
April 14, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…